ReviewJournal of medical case reports2026
Electrophysiological features and outcomes of post-infectious myoclonus-ataxia syndrome: a case report and literature review.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMyoclonus has become one of the neurological manifestations associated with coronavirus disease 2019 (COVID-19); however, the origin and pathophysiological mechanism remained uncertain. CASE PRESENTATION: A rare case of myoclonus-ataxia syndrome associated with COVID-19 was presented. A 52-year-old Asian woman exhibited generalized myoclonus, ataxia, nystagmus, and dysarthria two weeks after a fever episode, which deteriorated rapidly within a few days. Electromyography (EMG) revealed synchronized bursts in both hands concurrent with myoclonic jerks. The absence of somatosensory evoked potential and lack of correlation between electromyography (EEG) and EMG suggested a subcortical origin of the myoclonus. A post-infectious immune-mediated process was considered the most likely mechanism, given the latency from fever to myoclonus onset, and the absence of other possible etiologies. Treatment with intravenous methylprednisolone led to notable improvement and a good outcome at the two-month follow-up.
conclusionMyoclonus arising from subcortical structures can be associated with COVID-19. Early aggressive immunotherapy is important for a favorable outcome. Review of similar cases along with our report suggests COVID-19-associated myoclonus-ataxia as a distinct syndrome warranting prompt diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.